We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051
Read MoreHide Full Article
Sarepta Therapeutics, Inc. (SRPT - Free Report) announced data from the ongoing multiple ascending dose phase II study — MOMENTUM — evaluating its next-generation candidate, SRP-5051, for the treatment of Duchenne muscular dystrophy (DMD) by skipping exon 51. Data from the study showed that the candidate achieved proof-of-concept and supported continued dose escalation. This is the first clinical data from the company’s next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) platform. Data suggests that this platform will likely lead to improved efficacy and lower dosing compared to its PMO platform. The candidate was well tolerated in the study patient population.
The company’s PMO platform has been used to develop its two marketed drugs — Exondys 51 and Vyondys 53 — and lead pipeline candidate, casimersen, which is currently under review with the FDA. A decision is expected by Feb 25, 2021.
The company reported data from the group that received a monthly-dose of 20 mg/kg of SRP-5051 in the study. Data showed that the patients achieved higher tissue exposure, exon-skipping and dystrophin production at 12-weeks from baseline. Sarepta stated that while comparing MOMENTUM study data with data from previously completed PROMOVI study on Exondys 51, SRP-5051 showed improved efficacy with more convenient or lower dosing. SRP-5051 achieved 1.6-fold increase in exon skipping and a five-fold increase in the percentage of normal dystrophin compared to Exondys 51 at 24 weeks. Moreover, the PROMOVI study evaluated a weekly 30mg/kg of Exondys 51, significantly higher compared to SRP-5051 dose.
Sarepta observed that exon-skipping and dystrophin increases over time based on its experience with PMO-based drugs, suggesting further increase in efficacy for SRP-5051 with the passage of time. Based on these facts along with pre-clinical data, the company intends to continue to escalate doses of SRP-5051 and advance its PPMO exon-skipping pipeline for DMD that includes five other potential therapies.
So far this year, the company’s shares have increased 17% compared with the industry‘s rise of 5.7%.
Sarepta’s Exondys has seen steady growth in sales since its launch, reflecting potential in the DMD segment. SRP-5051, which is also exon-51 skipping candidate, seems to have encouraging potential following its successful launch.
Apart from its exon-skipping candidates, the company is developing several gene therapies targeting muscular dystrophies including DMD and central nervous system disorders. Its lead gene therapy candidate, SRP-9001, an AAV-mediated micro-dystrophin gene therapy candidate, is currently being evaluated in a phase I/II study for treating DMD. The promising candidate also led Roche (RHHBY - Free Report) to sign a collaboration deal with Sarepta related to commercialization of SRP-9001 in ex-U.S. markets.
However, we note that there are there are several other companies developing gene therapies for treating DMD including Solid Biosciences (SLDB - Free Report) , Audentes Therapeutics, and Pfizer (PFE - Free Report) . Successful development of gene therapies for DMD will increase competition in the field. Gene therapies of Solid Biosciences and Pfizer seemed to trail Sarepta’s gene therapy for DMD, based on early-stage study data.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Sarepta (SRPT) DMD Study Shows Proof of Concept for SRP-5051
Sarepta Therapeutics, Inc. (SRPT - Free Report) announced data from the ongoing multiple ascending dose phase II study — MOMENTUM — evaluating its next-generation candidate, SRP-5051, for the treatment of Duchenne muscular dystrophy (DMD) by skipping exon 51. Data from the study showed that the candidate achieved proof-of-concept and supported continued dose escalation. This is the first clinical data from the company’s next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) platform. Data suggests that this platform will likely lead to improved efficacy and lower dosing compared to its PMO platform. The candidate was well tolerated in the study patient population.
The company’s PMO platform has been used to develop its two marketed drugs — Exondys 51 and Vyondys 53 — and lead pipeline candidate, casimersen, which is currently under review with the FDA. A decision is expected by Feb 25, 2021.
The company reported data from the group that received a monthly-dose of 20 mg/kg of SRP-5051 in the study. Data showed that the patients achieved higher tissue exposure, exon-skipping and dystrophin production at 12-weeks from baseline. Sarepta stated that while comparing MOMENTUM study data with data from previously completed PROMOVI study on Exondys 51, SRP-5051 showed improved efficacy with more convenient or lower dosing. SRP-5051 achieved 1.6-fold increase in exon skipping and a five-fold increase in the percentage of normal dystrophin compared to Exondys 51 at 24 weeks. Moreover, the PROMOVI study evaluated a weekly 30mg/kg of Exondys 51, significantly higher compared to SRP-5051 dose.
Sarepta observed that exon-skipping and dystrophin increases over time based on its experience with PMO-based drugs, suggesting further increase in efficacy for SRP-5051 with the passage of time. Based on these facts along with pre-clinical data, the company intends to continue to escalate doses of SRP-5051 and advance its PPMO exon-skipping pipeline for DMD that includes five other potential therapies.
So far this year, the company’s shares have increased 17% compared with the industry‘s rise of 5.7%.
Sarepta’s Exondys has seen steady growth in sales since its launch, reflecting potential in the DMD segment. SRP-5051, which is also exon-51 skipping candidate, seems to have encouraging potential following its successful launch.
Apart from its exon-skipping candidates, the company is developing several gene therapies targeting muscular dystrophies including DMD and central nervous system disorders. Its lead gene therapy candidate, SRP-9001, an AAV-mediated micro-dystrophin gene therapy candidate, is currently being evaluated in a phase I/II study for treating DMD. The promising candidate also led Roche (RHHBY - Free Report) to sign a collaboration deal with Sarepta related to commercialization of SRP-9001 in ex-U.S. markets.
However, we note that there are there are several other companies developing gene therapies for treating DMD including Solid Biosciences (SLDB - Free Report) , Audentes Therapeutics, and Pfizer (PFE - Free Report) . Successful development of gene therapies for DMD will increase competition in the field. Gene therapies of Solid Biosciences and Pfizer seemed to trail Sarepta’s gene therapy for DMD, based on early-stage study data.
Sarepta Therapeutics, Inc. Price
Sarepta Therapeutics, Inc. price | Sarepta Therapeutics, Inc. Quote
Zacks Rank
Sarepta currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>